Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alagebrium in Chronic Heart Failure (BENEFICIAL)
NCT00516646Phase 2Completed
- Sponsor
- Synvista Therapeutics, Inc.
- Start
- Aug 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alagebrium in chronic heart failure (CHF), sponsored by Synvista Therapeutics, Inc.. Started Aug 2007; status: completed.
02
Drugs
alagebrium
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT00516646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516646.